

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Naltrexone-bupropion (prolonged release) for the managing overweight and obese
[ID757]

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Orexigen Therapeutics (naltrexone/bupropion prolonged-release) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Beat: Beating eating disorders • BEMDA: Black and Ethnic Minority Diabetes Association • Black Health Agency • Blood Pressure UK • British Cardiac Patients Association • British Obesity Society • Cardiovascular Care Partnership UK • Diabetes Research & Wellness Foundation • Diabetes UK • HEART UK • HOOP UK • InDependent Diabetes Trust • Muslim Health Network • National Obesity Forum • Network of Sikh Organisations • Overeaters Anonymous • South Asian Health Foundation • Specialised Healthcare Alliance • Surya Foundation • Weight Concern <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association for the Study of Obesity • Association of British Clinical Diabetologists • British Association for Nursing in Cardiac Care • British Cardiovascular Intervention Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British Cardiovascular Industry Association • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Diabetes UK Cymru • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> • Actavis (orlistat) • Almus pharmaceuticals (orlistat) • GlaxoSmithKline (orlistat, bupropion) • Roche (orlistat) • Teva UK (orlistat) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research • Cochrane Heart Group • Cochrane Metabolic & Endocrine Disorders Group • Cochrane Peripheral Vascular Disease Group • Cochrane Public Health Group

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Cardiovascular Society • British Dietetic Association • British Geriatrics Society • British Heart Foundation • British Hypertension Society • British Nutrition Foundation • Diabetes Specialist Nurses • Dieticians in Obesity Management • Faculty of Public Health Medicine • National Centre for Eating Disorders • National Diabetes Nurse Consultant Group • National Heart Forum UK • Primary Care Cardiovascular Society • Primary Care Diabetes Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science & Technology • Society for Endocrinology • Society for Vascular Technology • Society of Vascular Nurses • The Nutrition Society • The Obesity Management Association • United Kingdom Clinical Pharmacy Association • Vascular Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Bath and North East Somerset CCG • NHS England • NHS Fylde and Wyre CCG • Welsh Government 	<ul style="list-style-type: none"> • CORDA • MRC Clinical Trials Unit • National Institute for Health Research • Wellcome Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.